Certolizumab pegol

No definition available.

Endpoint definition

FinnGen phenotype data
diagram bullet diagram downward connector

Filter registries KELA purch., KELA reimb.

Medicine purchases: ATC L04AB05
Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

diagram downward connector RX_L04AB05

Extra metadata

First used in FinnGen datafreeze DF4

Summary Statistics

Key figures

All Female Male
Number of individuals 242 185 57
Unadjusted prevalence (%) 0.09 0.13 0.05
Mean age at first event (years) 47.33 46.46 50.18

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Correlations

Index endpoint: RX_L04AB05 – Certolizumab pegol
GWS hits:

Survival analyses between endpoints

Plot

before Certolizumab pegol
after Certolizumab pegol

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Certolizumab pegol